Biogen (BIIB) Stock Falls on Alzheimer's Drug Trial Death Reports
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Truist Securities Weighs in on Biogen (BIIB) Following 2nd Reported Alzheimer's Death
November 28, 2022 9:26 AM ESTTruist Securities analyst Robyn Karnauskas weighed in on Biogen (NASDAQ: BIIB) following recent news of the second death reported for Alzheimer's drug lecanemab. The analyst highlights:
The recent news and AEs of the drug raise lots of questions whether... MoreApple, Chevron, Biogen fall premarket; Univar, Pinduoduo rise
November 28, 2022 8:51 AM ESTBy Peter Nurse
Investing.com -- Stocks in focus in premarket trade on Monday, November 28th. Please refresh for updates.
Apple (NASDAQ: AAPL) stock fell 1.8% after a report indicated the tech giant will see a production shortfall of nearly 6 million iPhone Pro... More
Biogen (BIIB) on Watch Following Cautious Report in Science
November 28, 2022 7:13 AM ESTBiogen (NASDAQ: BIIB) on watch following cautious report in Science with the headline, "Second death linked to potential antibody treatment for Alzheimers disease."
... MoreBiogen (BIIB) option IV into Clinical Trials on Alzheimer's Congress
November 28, 2022 3:57 AM ESTBiogen (NASDAQ: BIIB) December weekly option implied volatility is at 55, December is at 51; compared to its 52-week range of 29 to 97 into data will be peer reviewed and presented Nov. 29 at the Clinical Trials on Alzheimer's Congress.
... MoreBiogen (BIIB) option IV into November 29 event
November 25, 2022 10:52 AM ESTBiogen (NASDAQ: BIIB) November weekly option implied volatility is at 31, December weekly is at 58, December is at 45; compared to its 52-week range of 29 to 97 into data will be peer reviewed and presented Nov. 29 at the Clinical Trials on Alzheimer's Congress.
... MoreBiogen (BIIB) option implied volatility into Clinical Trials on Alzheimer's Congress
November 25, 2022 4:49 AM ESTBiogen (NASDAQ: BIIB) November weekly option implied volatility is at 22, December weekly is at 55, December is at 56; compared to its 52-week range 29 to 97 into data will be peer reviewed and presented Nov. 29 at the Clinical Trials on Alzheimer's Congress.
... More